[Alzoon--antineoplastic remedy or medicinal syrup?].
Alzoon is a concoction containing extracts of petasites, juniper, ferns, brunellias, and dandelions that has been treated with oxygen and UV-light. A variety of indications are claimed: cachexia, severe pain, anemia as a result of malignant tumors, stomach or duodenal ulcers and also relief for desperate end-stage cancer patients. A long-term treatment is recommended. Prior to meals 2 to 3 times daily, 1-2 tablespoons of Alzoon are recommended. A bottle with 1 liter costs CHF 31.80. Apparently, Alzoon is harmless and free of side effects. Alzoon was patented in 1943 by the chemist M. R. von Niederhäusern from Basel. His company Alsana Inc. (pharmaceutical specialities, Thun, Switzerland) produces and sells Alzoon. A mechanism of action is not mentioned. Alzoon is sold as "holistic therapy", and is supposed to relieve pain, stimulate appetite, and enhance quality of life. The most important plant of the mixture is supposedly petasites. In the mid sixties a study on 42 patients was conducted under the pressure of the Alsana Inc. and v. Niederhäusern. The analysis of the results of the two experts showed that Alzoon had no influence on tumor growth. Six patients (14%) had a temporary improvement of quality of life and appetite. Further trials do not exist. In Switzerland, Alzoon is registered on the list D at the IKS, but is not reimbursable by insurance companies. It is not established as an anti-cancer remedy.
Hauser
S P
SP
Hämatologisches Zentrallabor, Inselspital/Universitätsspital, Bern.
D000284:Administration, Oral; D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D004366:Nonprescription Drugs; D010166:Palliative Care; D010936:Plant Extracts / Q000009:adverse effects / Q000627:therapeutic use*; D013557:Switzerland; D016896:Treatment Outcome
D000972:Antineoplastic Agents, Phytogenic; D004366:Nonprescription Drugs; D010936:Plant Extracts